M&A

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.

News

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK firm's shareholders.

News

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.

News

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.